Holen Sie sich die Stockscreener-App
9.41
3.42%
-0.39
Handel nachbörslich:
9.41
Schlusskurs vom Vortag:
$9.80
Offen:
$9.76
24-Stunden-Volumen:
2.44M
Relative Volume:
1.25
Marktkapitalisierung:
$690.86M
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-2.015
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
+1.77%
1M Leistung:
+22.29%
6M Leistung:
+27.91%
1J Leistung:
-63.13%
1-Tages-Spanne:
$9.29
$9.87
1-Wochen-Bereich:
$9.225
$9.945
52-Wochen-Spanne:
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Vergleichen Sie ARVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
9.41 | 694.53M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2025-06-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Herabstufung | Truist | Buy → Hold |
| 2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Is Arvinas Inc. trending in predictive chart models2025 Price Momentum & AI Enhanced Trading Signals - newser.com
Can Arvinas Inc. stock beat analyst upgradesWeekly Investment Recap & Capital Efficient Trading Techniques - newser.com
Can Arvinas Inc. stock withstand economic slowdownQuarterly Profit Summary & Daily Volume Surge Signals - newser.com
What data driven models say about Arvinas Inc.’s futureGap Down & Fast Entry and Exit Trade Plans - newser.com
Published on: 2025-10-13 09:51:45 - newser.com
Chart overlay techniques for tracking Arvinas Inc.July 2025 Trade Ideas & Capital Efficient Trading Techniques - newser.com
How to forecast Arvinas Inc. trends using time seriesProduct Launch & Weekly High Conviction Ideas - newser.com
Arvinas, Inc. to Present New Patient-Reported Outcomes Data for Vepdegestrant at ESMO Congress 2025 - Quiver Quantitative
Arvinas to Present Data from the Vepdegestrant Clinical - GlobeNewswire
Phase 3 PRO data lead: Arvinas' vepdegestrant to be presented at ESMO Oct 19–20, 2025 in Berlin - Stock Titan
What MACD signals say about Arvinas Inc.Earnings Miss & High Conviction Buy Zone Alerts - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
Full technical analysis of Arvinas Inc. stockTrade Risk Report & Daily Profit Maximizing Tips - newser.com
Arvinas’s SWOT analysis: vepdeg promise, pipeline shifts shape stock outlook By Investing.com - Investing.com South Africa
Arvinas’s SWOT analysis: vepdeg promise, pipeline shifts shape stock outlook - Investing.com
Arvinas Holding Company (ARVN) Receives a Hold from Bank of America Securities - The Globe and Mail
Piper Sandler raises Arvinas stock price target to $16 on LRRK2 degrader data - Investing.com
Arvinas Announces Positive Phase 1 Trial Results - TipRanks
Arvinas Says Potential Parkinson's Disease Treatment Well Tolerated in Early Trials; Shares Gain Pre-Bell - MarketScreener
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Top Companies in Targeted Protein Degradation MarketBristol - openPR.com
Is Arvinas Inc. reversing from oversold territoryShort Setup & Weekly Chart Analysis and Guides - newser.com
Full Stock Market News from 2025-10-05 - Stock Titan
Arvinas (ARVN) Highlights Promising Phase 1 Trial Results for AR - GuruFocus
Arvinas reports positive data for LRRK2 degrader in Parkinson’s trials By Investing.com - Investing.com Nigeria
Arvinas reports positive data for LRRK2 degrader in Parkinson’s trials - Investing.com India
Arvinas, Inc. Reports Positive Phase 1 Trial Results for ARV-102 in Healthy Volunteers and Parkinson's Disease Patients - Quiver Quantitative
Arvinas Presents Late Breaking, Positive Phase 1 Clinical - GlobeNewswire
97% LRRK2 Reduction — Arvinas' ARV-102 Shows Strong PBMC Target Engagement and CSF Biomarker Modulation - Stock Titan
Will a bounce in Arvinas Inc. offer an exitJuly 2025 News Drivers & Weekly Breakout Opportunity Watchlist - newser.com
Real time alert setup for Arvinas Inc. performanceJuly 2025 Catalysts & Reliable Entry Point Trade Alerts - newser.com
Is Arvinas Inc. stock poised for growthQuarterly Market Review & Real-Time Sentiment Analysis - newser.com
Tools to monitor Arvinas Inc. recovery probabilityWeekly Loss Report & Real-Time Volume Analysis - newser.com
Can Arvinas' Brain-Penetrant PROTAC Deliver On Its Promise In Parkinson's Trials? - RTTNews
Voya Investment Management LLC Has $124,000 Holdings in Arvinas, Inc. $ARVN - Defense World
Using fundamentals and technicals on Arvinas Inc.July 2025 Outlook & Safe Capital Preservation Plans - newser.com
Arvinas, Inc. to Present Clinical Data for Investigational PROTAC LRRK2 Degrader ARV-102 at MDS 2025 Conference - Quiver Quantitative
Arvinas to Present Clinical Data for ARV-102, a PROTAC - GlobeNewswire
First-Ever PROTAC LRRK2 Degrader Human Trial Data: Arvinas Reveals Breakthrough Parkinson's Results - Stock Titan
What drives Arvinas Inc stock priceTechnical Pattern Recognition & Low Risk Investment Portfolio - earlytimes.in
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arvinas Inc-Aktie (ARVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Saik Andrew | Chief Financial Officer |
Jun 24 '25 |
Sale |
7.61 |
5,700 |
43,377 |
164,401 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):